Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 8/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6648662 | 0.92 | SLC2A1 (0.60) | SLC2A1KCNH2CYP2D6KDM4EALDH1A1 | |
| SCHEMBL6498401 | 0.92 | SLC2A1 (0.60) | SLC2A1KCNH2CYP2D6KDM4EALDH1A1 | |
| SCHEMBL6645394 | 0.92 | SLC2A1 (0.60) | SLC2A1KCNH2CYP2D6KDM4EALDH1A1 | |
| SCHEMBL6497372 | 0.92 | SLC2A1 (0.60) | SLC2A1KCNH2CYP2D6KDM4EALDH1A1 | |
| SCHEMBL6648669 | 0.92 | SLC2A1 (0.60) | SLC2A1KCNH2CYP2D6KDM4EALDH1A1 | |
| SCHEMBL6498397 | 0.92 | SLC2A1 (0.60) | SLC2A1KCNH2CYP2D6KDM4EALDH1A1 | |
| SCHEMBL6645390 | 0.92 | SLC2A1 (0.60) | SLC2A1KCNH2CYP2D6KDM4EALDH1A1 | |
| SCHEMBL6645387 | 0.92 | SLC2A1 (0.60) | SLC2A1KCNH2CYP2D6KDM4EALDH1A1 | |
| SCHEMBL6498402 | 0.92 | SLC2A1 (0.60) | SLC2A1KCNH2CYP2D6KDM4EALDH1A1 | |
| Oxalic Acid SCHEMBL6486309 | 0.88 | SLC2A1 (0.60) | SLC2A1KCNH2CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6803369-B1 | INHIBIT A BIOLOGICAL ACTIVITY OF A TOPOISOMERASE ENZYMES | SMITHKLINE BEECHAM CORPORATION | 2004-10-12 | — | — | US | claimed |
| US-20030203917-A1 | Compounds and methods for the treatment of neoplastic disease | SMITHKLINE BEECHAM CORPORATION AND SMITHKLINE BEECHAM P.L.C. | 2003-10-30 | — | — | US | claimed |
| US-6803369-B1 | INHIBIT A BIOLOGICAL ACTIVITY OF A TOPOISOMERASE ENZYMES | SMITHKLINE BEECHAM CORPORATION | 2004-10-12 | — | — | US | disclosed |
| US-20030203917-A1 | Compounds and methods for the treatment of neoplastic disease | SMITHKLINE BEECHAM CORPORATION AND SMITHKLINE BEECHAM P.L.C. | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203917-A1 | Compounds and methods for the treatment of neoplastic disease | TOP1, TOP2A, TOP2B | SLC2A1 3716/4885KCNH2 4586/4885CYP2D6 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.